Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Scher, H. I.
Beer, T. M.
Higano, C. S.
Taplin, M.
Efstathiou, E.
Anand, A.
Hung, D.
Hirmand, M.
Fleisher, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Univ Washington, SCCA, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Medivation Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [23] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [24] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [25] ANTITUMOUR ACTIVITY OF MDV3100 IN A PHASE 1-2 STUDY OF ADVANCED PROSTATE CANCER
    Scher, H. I.
    Beer, T. M.
    Higano, C.
    Taplin, M.
    Efstathiou, E.
    Hirmand, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 285 - 285
  • [26] TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC).
    Baskin-Bey, Edwina S.
    Shore, Neal D.
    Barber, Kenya
    Ouatas, Taoufik
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] CLINICAL ACTIVITY OF ABIRATERONE ACETATE (AA) AFTER PROGRESSION ON MDV3100 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
    Noonan, K.
    Ellard, S.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 305 - 305
  • [28] Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study
    Higano, C. S.
    Beer, T. M.
    Taplin, M.
    Efstathiou, E.
    Anand, A.
    Hirmand, M.
    Fleisher, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [29] CIRCULATING TUMOR CELLS (CTC) AND PROSTATE-SPECIFIC ANTIGEN (PSA) AS RESPONSE INDICATOR BIOMARKERS IN CHEMOTHERAPY-NAIVE PATIENTS WITH PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED WITH MDV3100
    Hirmand, M.
    Scher, H. I.
    Beer, T.
    Higano, C. S.
    Taplin, M.
    Efstathiou, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 277 - 277
  • [30] CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY
    Morgan, C.
    McEwan, P.
    Chamberlain, G.
    Cabrera, C.
    Parry, D.
    VALUE IN HEALTH, 2010, 13 (03) : A26 - A26
12345